<DOC>
	<DOCNO>NCT02972567</DOCNO>
	<brief_summary>The purpose study evaluation effect obese patient metabolic syndrome composition intestinal microbiota , marker syndrome ( hypertension , dyslipidemia , inflammation biomarkers , risk cardiovascular hepatic steatosis ) possible metabolite involve .</brief_summary>
	<brief_title>Evaluation Effects L.Reuteri Strain Markers Inflammation , Cardiovascular Risk Fatty Liver Disease</brief_title>
	<detailed_description>Randomized double blind crossover placebo control intervention study The propose study conduct member Endocrinology Nutrition Services ( ENCHJ ) , Gastroenterology ( ADCHJ ) , Hospital Jaen member Department Biochemistry Molecular Biology II University Granada ( UGR ) member Microbiology Department University Hospital San Cecilio Granada ( MHUSC ) . The selection , clinical anthropometric control , general biochemical parameter determination hepatic steatosis ultrasound perform member ENCHJ . The determination composition intestinal microbiota carry member UGR together member form MHUSC . Inflammation steatosis biomarkers well metabolic profile perform member UGR . The study conduct accord Helsinki Rules previously approve Ethics Committee Research Jaen . The study follow rule international , national regional research The biological sample manage process accordance research protocols Biobanco del Sistema Sanitario Público de Andalucía . At end project , sample store within framework Biobank Public Health Organization Andalusia . The present study involve access use information confidential , data treat anonymously . • Sample size assessment specify number participant participant year necessary demonstrate effect . Based range median value plasma lipopolysaccharide ( LPS ) , assume power 90 % type error alpha 5 % , minimum number subject 32 . To avoid possible bias cause gender take account withdrawal , recruit 60 subject . The miss data consider unavailable data . All statistical analysis perform use statistical package SPSS ( Statistical Product Service Solutions ) . Normally distribute data express mean standard error mean , whereas median range use data normally distribute .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<criteria>Patients diagnosis insulin resistance syndrome , accord Criteria International Diabetes Federation ( IDF ) BMI &gt; 30 kg/m2 Waist Circumference ≥ 94cm ( men ) WC≥ 80cm ( woman ) Serum Triglycerides ≥ 150 mg/dl HDLcholesterol &lt; 40 mg/dl ( 1,03 mmol/l ) men &lt; 50 mg/dl ( 1,29 mmol/l ) woman Systolic blood pressure ≥ 130 mmHg diastolic ≥ 85 mmHg Glucose ≥ 100 mg/dl ( 5,6 mmol/l ) ( previous diagnostic diabetes II ) Patients renal hepatic impairment Patients diagnosis diabetes Patients diseases condition immunosuppression Patients present positive serology liver virus Being antihypertensive treatment : betablockers , Angiotensin 2 receptor antagonist ( ARA 2 ) , enzyme inhibitor , Angiotensin convert enzyme ( ACE ) inhibitor . Patients receive lipidlowering / hypoglycemic agent Patients treatment drug increase hepatic enzyme , Amiodarone , perhexiline , maleate 4,4'diethylaminoethoxyhexestrol , synthetic estrogen , Tamoxifen , corticosteroid , acetylsalicylic acid , Valproic acid , tetracycline , viral agent ( zidovudine , zalcitabine , didanosine ) , among others . Exhibiting high value Creactive protein ( CRP ) Sedimentation ( ESR ) Consuming alcohol quantity great 40 g / hepatotoxic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>probiotic</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>non-alcoholic fatty liver disease</keyword>
</DOC>